185 related articles for article (PubMed ID: 29464755)
1. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance.
Kiyohara Y; Uhara H; Ito Y; Matsumoto N; Tsuchida T; Yamazaki N
J Dermatol; 2018 Apr; 45(4):408-415. PubMed ID: 29464755
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance.
Uhara H; Tsuchida T; Kiyohara Y; Akamatsu A; Sakamoto T; Yamazaki N
J Dermatol; 2022 Sep; 49(9):862-871. PubMed ID: 35607248
[TBL] [Abstract][Full Text] [Related]
3. Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance.
Yamazaki N; Kiyohara Y; Uhara H; Tsuchida T; Maruyama K; Shakunaga N; Itakura E; Komoto A
J Dermatol; 2020 Aug; 47(8):834-848. PubMed ID: 32515086
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.
Yamamoto N; Nakanishi Y; Gemma A; Nakagawa K; Sakamoto T; Akamatsu A; Ohe Y
Cancer Sci; 2021 Nov; 112(11):4692-4701. PubMed ID: 34431585
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Tsuchida T; Yoshida A; Yamada T; Komoto A
J Dermatol; 2023 Sep; 50(9):1108-1120. PubMed ID: 37350027
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab: a review of its use in patients with malignant melanoma.
Deeks ED
Drugs; 2014 Jul; 74(11):1233-9. PubMed ID: 25022950
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
10. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
11. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Freeman-Keller M; Kim Y; Cronin H; Richards A; Gibney G; Weber JS
Clin Cancer Res; 2016 Feb; 22(4):886-94. PubMed ID: 26446948
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.
Uhara H; Kiyohara Y; Tsuda A; Takata M; Yamazaki N
Clin Transl Oncol; 2018 Feb; 20(2):169-175. PubMed ID: 28674996
[TBL] [Abstract][Full Text] [Related]
16. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
18. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Gibney GT; Kudchadkar RR; DeConti RC; Thebeau MS; Czupryn MP; Tetteh L; Eysmans C; Richards A; Schell MJ; Fisher KJ; Horak CE; Inzunza HD; Yu B; Martinez AJ; Younos I; Weber JS
Clin Cancer Res; 2015 Feb; 21(4):712-20. PubMed ID: 25524312
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
D'Angelo SP; Larkin J; Sosman JA; Lebbé C; Brady B; Neyns B; Schmidt H; Hassel JC; Hodi FS; Lorigan P; Savage KJ; Miller WH; Mohr P; Marquez-Rodas I; Charles J; Kaatz M; Sznol M; Weber JS; Shoushtari AN; Ruisi M; Jiang J; Wolchok JD
J Clin Oncol; 2017 Jan; 35(2):226-235. PubMed ID: 28056206
[TBL] [Abstract][Full Text] [Related]
20. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study).
Yamazaki N; Takenouchi T; Nakamura Y; Takahashi A; Namikawa K; Kitano S; Fujita T; Kubota K; Yamanaka T; Kawakami Y
Jpn J Clin Oncol; 2021 Aug; 51(8):1232-1241. PubMed ID: 34115870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
